Equity · Healthcare
PROF
NASDAQProfound Medical (PROF)
The line runs 7 USD on 18 August through 7.43 USD on 13 November, on a scale from 5 to 8. Days the market did not trade hold the previous close, flat.
- Market cap
- 272.1M USD
- P/E (TTM)
- 4.8
- Revenue, year to Dec 2025
- 16.1M USD
- EPS, diluted, year to Dec 2025
- 1.41 USD
- Next earnings
- 31 Dec 2026
- 52-week range
- 5.08 USD – 8.69 USD
- Avg volume
- 11.6K
- Mentions, 30 days
- 18
- Net sentiment
- +0.05
as of Nov 13, 2026
Which funds hold Profound Medical (PROF)?
1 of the 45 institutional funds we track reported a Profound Medical position for the quarter ended 30 Sep 2026 — a combined 68K USD; the latest of those filings landed 12 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Renaissance Technologies | New position | 11,700 | 68K USD |
What has been filed or recorded for Profound Medical (PROF)?
The filings we hold for Profound Medical, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 13 Oct 2026. Next report: 31 Dec 2026.
| And | ||||
|---|---|---|---|---|
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 255 shares | 2K USD notional · 0.001% of shares out |
| 07 Oct 2026 | Fails to deliver | Shares failed to deliver | 8,106 shares | 49K USD notional · 0.022% of shares out |
| 05 Oct 2026 | Fails to deliver | Shares failed to deliver | 2,246 shares | 13K USD notional · 0.006% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.21 USD | Revenue $10M |
| 30 Sep 2026 | Financials | Total assets | 58.2M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 42.5M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.26 USD | Revenue $2M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.19 USD | Revenue $5M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 1.41 USD | Revenue $16M |
| 31 Dec 2025 | Financials | Revenue | 16.1M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −42.6M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 1.41 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.26 USD | Revenue $5M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.52 USD | Revenue $2M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.36 USD | Revenue $3M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS 1.12 USD | Revenue $11M |
What is Reddit saying about Profound Medical (PROF)?
Reddit mentioned PROF 18 times in the 30 days to 16 November 2026, across 5 of the communities we track. All of them were scored for sentiment: 39% read bullish, 11% bearish and 50% neither. Reddit data updated 16 November 2026.
30-day window, Method
How do Reddit mentions of Profound Medical (PROF) compare with its price?
Share ↗
Which subreddits are talking about Profound Medical (PROF)?
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 61% | 11 | +0.08 |
| r/stocks | 22% | 4 | +0.01 |
| r/ausfinance | 6% | 1 | +0.02 |
| r/cryptocurrency | 6% | 1 | −0.11 |
| r/investing | 6% | 1 | +0.03 |
Which names move with Profound Medical (PROF) on Reddit?
VEQT moved most closely with Profound Medical (PROF): when the crowd talked about one, it talked about the other (+0.74 over 31 days). Co-discussion, not price.
VEQT | ||||||
|---|---|---|---|---|---|---|
PROF | +0.74 | +0.71 | +0.69 | +0.68 | +0.68 | +0.67 |
View the matrix as a tableHide the table
| Pair | Match | Days measured |
|---|---|---|
| PROF and VEQT | +0.74 | 31 days |
| PROF and Rolex | +0.71 | 31 days |
| PROF and QQQI | +0.69 | 31 days |
| PROF and CAT | +0.68 | 31 days |
| PROF and PPT | +0.68 | 31 days |
| PROF and TQQQ | +0.67 | 31 days |
What do people ask about Profound Medical (PROF)?
What did Profound Medical shares close at?7.43
Profound Medical closed at 7.43 USD on 13 Nov 2026, up 0.07% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Profound Medical’s market cap?272.1M
Profound Medical is worth 272.1M USD by market value as of 13 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Profound Medical’s P/E ratio?4.8
Profound Medical has a price-to-earnings ratio of 4.8, as of 13 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Profound Medical’s revenue?16.1M
Profound Medical reported revenue of 16.1M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Which funds own Profound Medical?1 of 45
1 of the 45 funds we track reported a Profound Medical position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Renaissance Technologies. See Funds
When did Profound Medical last report earnings?−0.21
Profound Medical last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.21 USD; the next report is scheduled for 31 Dec 2026 (SEC filings). See Filings
What is Reddit saying about Profound Medical?1 mentions
Profound Medical was mentioned 1 times in the last 7 days across the finance subreddits we track, and 18 times over the trailing 30 days. Of the 18 mentions scored for sentiment, 39% read bullish and 11% bearish. That is a social signal, not investment advice. See Reddit

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings